Human IgG responses against the N-terminal region of Merozoite Surface Protein 1 of Plasmodium vivax

Portillo, Hernando A. del; Levitus, Gabriela; Camargo, Luiz Octávio de Lima; Ferreira, Marcelo Urbano; Mertens, Frédéric

doi:10.1590/s0074-02761992000700010

Cited by 4 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(C) Main access of community of Rio Pardo is via a paved road (BR-174) that connects the states of Amazonas and Roraima. (D) The settlement is comprised of households located along both sides of unpaved roads, which is a typical deforestation pattern in the Amazon [33]. Rio Pardo outline by Sylvain JM Desmoulière – ILMD.…”

Section: Methodsmentioning

confidence: 99%

“…The recombinant protein ICB2-5 (representing the N-terminus of Pv-MSP1) comprises three conserved blocks (Blocks 1, 3, and 5) and two variable blocks (Blocks 2 and 4) from the MSP1 protein of Belem strain as glutathione S-transferase (GST) fusion proteins [27-30,33]. As a control, GST alone was also produced.…”

Section: Methodsmentioning

confidence: 99%

“…As such, it has considerable potential as a candidate target for vaccine design and/or clinical trials [27-32]. Although short-lived, P. vivax MSP1 (referred to as Pv-MSP1) humoral immune response has been shown to be mostly against the polymorphic domains [27,28,33-35]. In individuals clinically protected from malaria, high levels of antibodies against a polymorphic domain in the N-terminus of Pv-MSP1 [30].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms

Versiani

Almeida

Melo

et al. 2013

Malar J

View full text Add to dashboard Cite

BackgroundPlasmodium vivax has the potential to infect 2.85 billion individuals worldwide. Nevertheless, the limited number of studies investigating the immune status of individuals living in malaria-endemic areas, as well as the lack of reports investigating serological markers associated with clinical protection, has hampered development of vaccines for P. vivax. It was previously demonstrated that naturally total IgG against the N-terminus of P. vivax merozoite surface protein 1 (Pv-MSP1) was associated with reduced risk of malarial infection.MethodsImmune response against Pv-MSP1 (N-terminus) of 313 residents of the Rio Pardo rural settlement (Amazonas State, Brazil) was evaluated in a cross-sectional and longitudinal follow up over two months (on site) wherein gold standard diagnosis by thick blood smear and rRNA gene-based nested real-time PCR were used to discriminate symptomless Plasmodium vivax-infected individuals who did not develop clinical symptoms during a 2-months from those uninfected ones or who have had acute malaria. The acquisition of antibodies against Pv-MSP1 was also evaluated as survival analysis by prospective study over a year collecting information of new malaria infections in surveillance database.ResultsThe majority of P. vivax-infected individuals (52-67%) showed immune recognition of the N-terminus of Pv-MSP1. Interesting data on infected individuals who have not developed symptoms, total IgG levels against the N-terminus Pv-MSP1 were age-dependent and the IgG3 levels were significantly higher than levels of subjects had acute malaria or those uninfected ones. The total IgG anti ICB2-5 was detected to be an important factor of protection against new malaria vivax attacks in survival analysis in a prospective survey (p = 0.029).ConclusionsThe study findings illustrate the importance of IgG3 associated to 2-months of symptomless in P. vivax infected individuals and open perspectives for the rationale of malaria vaccine designs capable to sustain high levels of IgG3 against polymorphic malaria antigens.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms

Versiani

Almeida

Melo

et al. 2013

Malar J

View full text Add to dashboard Cite

show abstract

“…The N-terminal region of the MSP1 of P. vivax (PvMSP1) has been expressed in Escherichia coli (8,21,23) and in Saccharomyces cerevisiae cells (13). In a study performed in Brazil, it was reported that the N-terminal region of PvMSP1 was immunogenic.…”

mentioning

confidence: 99%

Naturally Acquired Antibody Responses to the C-Terminal Region of Merozoite Surface Protein 1 ofPlasmodium vivaxin Korea

Park¹,

Moon²,

Yeom

et al. 2001

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

We expressed a protein in Saccharomyces cerevisiae in order to evaluate the humoral immune responses to the C-terminal region of the merozoite surface protein 1 of Plasmodium vivax. This protein (Pv200 18 ) had a molecular mass of 18 kDa and was reactive with the sera of individuals with patent vivax malaria on immunoblotting analysis. The levels of immunoglobulin M (IgM) and IgG antibodies against Pv200 18 were measured in 421 patients with vivax malaria (patient group), 528 healthy individuals from areas of nonendemicity (control group 1), and 470 healthy individuals from areas of endemicity (control group 2), using the indirect enzyme-linked immunosorbent assay (ELISA) method. To study the longevity of the antibodies, 20 subjects from the patient group were also tested for the antibody levels once a month for 1 year. When the cutoff values for seropositivity were determined as the mean ؉ 3 ؋ standard deviation of the antibody levels in control group 1, both IgG and IgM antibody levels were negative in 98.5% (465 of 472) of control group 2. The IgG and IgM antibodies were positive in 88.1% (371 of 421) and 94.5% (398 of 421) of the patient group, respectively. The IgM antibody became negative 2 to 4 months after the onset of symptoms, whereas the IgG antibody usually remained positive for more than 5 months. In conclusion, indirect ELISA using Pv200 18 expressed in S. cerevisiae may be a useful diagnostic method for vivax malaria.

show abstract

“…Despite being a potential target for vaccine development, the MSP1 protein of P. vivax (PvMSP1) has been the subject of relatively few studies. The N-terminal region of PvMSP1 was expressed in Escherichia coli (17,27,30) and yeast cells (22), and the products were tested by enzyme-linked immunosorbent assay (ELISA) or Western blot analyses with sera of individuals with patent malaria infections from Brazil. The results demonstrated that similarly to PfMSP1, the N-terminal region of PvMSP1 is immunogenic in natural infections; however, 40% of the individuals with patent infections did not contain detectable levels of immunoglobulin (IgG) antibodies to the recombinant proteins representing the N-terminal region of PvMSP1, even after multiple attacks of malaria.…”

mentioning

confidence: 99%

Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria

et al. 1997

View full text Add to dashboard Cite

In this study, we evaluated the naturally acquired immune response to Plasmodium vivax merozoite surface protein 1 (PvMSP1) in individuals with recent clinical episodes of malaria from the state of Pará, Brazil. Ten recombinant proteins representing the first 682 amino acids (aa) of the N-terminal region and one representing the final 111 aa of the C-terminal region were expressed in Escherichia coli as glutathione S-transferase fusion proteins. Both of these regions have been suggested as candidates for development of a vaccine against Plasmodium sp. The total frequencies of individuals with antibodies and cellular immune responses to PvMSP1 were high (83.8 and 75%, respectively). The recombinant proteins representing the N-and C-terminal regions were recognized by 51.4 and 64.1% of sera, respectively. The frequency of responders to the C-terminal region increased according to the number of previous malaria episodes, reaching 83.3% after four episodes. Cellular immune response was measured by in vitro proliferation and gamma interferon production. Peripheral blood mononuclear cells of 75 and 47.2% of individuals proliferated in response to stimulation by the N-and C-terminal regions, respectively. Also, we found that one protein representing the N terminus and a second representing the C terminus of PvMSP1 stimulated 54.5% of individuals to secrete gamma interferon. We concluded that PvMSP1 is immunogenic to a large proportion of individuals exposed to malaria. Our results also suggested that the C-terminal region of PvMSP1 containing the two epidermal growth factor-like domains is particularly immunogenic to antibodies and T cells during natural infection in humans.

show abstract

Human IgG responses against the N-terminal region of Merozoite Surface Protein 1 of Plasmodium vivax

Cited by 4 publications

References 0 publications

High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms

High levels of IgG3 anti ICB2-5 in Plasmodium vivax-infected individuals who did not develop symptoms

Naturally Acquired Antibody Responses to the C-Terminal Region of Merozoite Surface Protein 1 ofPlasmodium vivaxin Korea

Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria

Contact Info

Product

Resources

About